This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
The company has developed a proprietary new drug class called Lipid Analogue Therapeutics. Ability Pharmaceuticals has two drugs candidates in development in several cancer types:
? ABTL0812 which starts Phase I/Ib clinical trials (First in Humans) in October 2013: Preclinical data has shown efficacy in lung cancer and pancreatic cancer.
? ABTL1014 is in preclinical development and targets hematologic malignancies.
The company develops the new drug candidates up through clinical proof of concept, and will then out-license them to biopharmaceutical companies for further development.
The company participates in this convention to raise funds for the phase II clinical program of ABTL0812, to fund the preclinical development of ABTL1014 and to fully exploit its patented drug discovery platform to generate new anti-cancer drug candidates.
ADVANCELL is seeking for partners with significant development and marketing capabilities to further develop and commercialize ATH012 (MS) and ATH001 (oncology).
Allinky Biopharma is a start-up company-associated to academia-that focuses its activities on the discovery and development of small molecules to treat chronic inflammatory conditions, age-related degenerative diseases and cancer. Based on recent advances in molecular medicine, Allinky proposes to improve the treatment of these prevalent pathologies by addressing their molecular origins, and by following nature's strategy to control the excess activation of a given protein using a novel class of therapeutic agents: allosteric modulators.
Grifols investment vehicle, Gri-Cel S.A. currently owns shares of Araclon Biotech (51% equity share),
The founders gather nearly 30 years of Pioneer international recognized industrial experience in Controlled Release Drug Therapeutics (peptides, proteins and chemicals) and have demonstrated their ability to innovate from idea to commercialized products (broad patents portfolio generated +drug products commercially launched www )
Our team gathers a Unique Cluster of skills and Know-how with impressive track record of achievements in well-established public and private pharma co.
Our mission is to create
New Improved Pharmaceutical and Biotech Therapeutic treatments providing Sustainable differentiations & generating value thanks to Innovative Drug Delivery Platforms and a Team with a Unique Expertise.
Our experience covers :
- From the idea up to the commercial products
- From once daily delivery to more than 6 months injectable SRF
- Biodegradable and Non-Biodegradable approaches
- From STD Lyophilised forms to Ready to use prefilled systems
- From basic research to GMP regulatory compliance (EMA,FDA,JP)
- From the nanosystems and sciences to the millimeters scale
- From BCN to the world collaboration
- From being a Client to being a Provider (with major big pharma)
- From private to public companies/ partnership